We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$115B
AUM Growth
+$6.24B
Cap. Flow
+$1B
Cap. Flow %
0.87%
Top 10 Hldgs %
23.71%
Holding
4,165
New
247
Increased
1,898
Reduced
1,581
Closed
296

Sector Composition

Rank Sector Weight
1 Technology 14.47%
2 Healthcare 8.69%
3 Financials 8.53%
4 Industrials 6.69%
5 Consumer Discretionary 5.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NEXI
3601
DELISTED
NexImmune, Inc. Common Stock
NEXI
$122K ﹤0.01%
12,825
+11,600
+947% +$122K
UEIC icon
3602
Universal Electronics
UEIC
$66.6M
$122K ﹤0.01%
11,991
-13,145
-52% -$229K
VZ icon
3603
PUT
Verizon
VZ
$200B
$122K ﹤0.01%
+2,700
New +$106K
MFIN icon
3604
Medallion Financial
MFIN
$262M
$121K ﹤0.01%
15,725
GLAD icon
3605
Gladstone Capital
GLAD
$452M
$120K ﹤0.01%
6,390
TSLA icon
3606
CALL
Tesla
TSLA
$1.34T
$120K ﹤0.01%
+600
New +$105K
STNE icon
3607
StoneCo
STNE
$2.49B
$120K ﹤0.01%
12,550
+1,167
+10% +$11.2K
SFYX
3608
DELISTED
SoFi Next 500 ETF
SFYX
$118K ﹤0.01%
+10,306
New +$120K
SUZ icon
3609
Suzano
SUZ
$9.84B
$118K ﹤0.01%
14,323
-3,397
-19% -$30.4K
NPCT icon
3610
Nuveen Core Plus Impact Fund
NPCT
$284M
$117K ﹤0.01%
11,455
-673
-6% -$7.32K
NGM
3611
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$117K ﹤0.01%
28,576
+303
+1% +$1.4K
TPC
3612
Tutor Perini Cor
TPC
$4.98B
$116K ﹤0.01%
18,863
GOGL
3613
DELISTED
Golden Ocean Group
GOGL
$116K ﹤0.01%
12,172
-52
-0.4% -$492
GLV
3614
Clough Global Dividend & Income Fund
GLV
$78.3M
$116K ﹤0.01%
20,015
-498
-2% -$3.05K
CEPU
3615
Central Puerto
CEPU
$1.99B
$115K ﹤0.01%
+21,321
New +$127K
OPP
3616
RiverNorth/DoubleLine Strategic Opportunity Fund
OPP
$192M
$115K ﹤0.01%
13,622
-98
-0.7% -$846
EPD icon
3617
PUT
Enterprise Products Partners
EPD
$82.1B
$115K ﹤0.01%
+5,000
New +$128K
PATI
3618
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
$115K ﹤0.01%
14,326
+957
+7% +$7.47K
PANL icon
3619
Pangaea Logistics
PANL
$496M
$114K ﹤0.01%
19,485
AVXL icon
3620
Anavex Life Sciences
AVXL
$303M
$113K ﹤0.01%
+13,195
New +$132K
MIXT
3621
DELISTED
MIX TELEMATICS LIMITED
MIXT
$113K ﹤0.01%
14,531
-2,384
-14% -$19.1K
GGAL icon
3622
Galicia Financial Group
GGAL
$7.23B
$112K ﹤0.01%
+10,214
New +$126K
CMPS
3623
Compass Pathways
CMPS
$1.84B
$111K ﹤0.01%
11,128
-5,963
-35% -$54.9K
EXAI
3624
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$110K ﹤0.01%
+20,828
New +$141K
SLI
3625
Standard Lithium
SLI
$574M
$110K ﹤0.01%
28,897
-9,750
-25% -$38K

Similar funds

Raymond James & Associates's Q1 2023 Portfolio in Review

As of Q1 2023, Raymond James & Associates held 4,165 positions worth $115B, up 5.7% from $109B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q1 2023 filing shows 247 new, 1,898 increased, 1,581 reduced and 296 closed positions. Its largest new stake was VanEck Morningstar International Moat ETF: 787,215 shares worth $25.2M. The largest sale was iShares MSCI USA Min Vol Factor ETF, an estimated $551M.

By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q1 2023 buy was VanEck Morningstar International Moat ETF: 787,215 shares worth $25.2M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q1 2023, an estimated $413M increase.
  • Raymond James & Associates's biggest Q1 2023 reduction was iShares MSCI USA Min Vol Factor ETF, cutting an estimated $551M.
  • Raymond James & Associates fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $18.8M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $115B portfolio in Q1 2023.
  • Raymond James & Associates opened 247 new positions and closed 296 in Q1 2023.
  • Raymond James & Associates's portfolio value rose 5.7% quarter-over-quarter to $115B.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.